Document:

EX-10.8

 Exhibit 10.8 

DIRECTOR AGREEMENT 

This DIRECTOR AGREEMENT (the “Agreement”), is made and entered into as of this
15th day of July 2016 and effective as of July 1, 2016 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Seth
Rudnick, MD (“Board Member”). This Agreement replaces that certain Director Agreement, effective July 1, 2014, by and between the Company and the Board Member, which expired by its terms on June 30, 2016. 

1.    APPOINTMENT; DUTIES. The Company hereby retains Board Member to, and Board Member hereby agrees to, serve as
a member of and Chairman of the Company’s Board of Directors (the “Board”), subject to any required Board and/or security holder approval. As a member and Chairman of the Board, Board Member will be expected to (i) attend any
meetings of the Board; (ii) lead Board meetings and conference calls; (iii) provide guidance and advice to the Company on matters and developments potentially relevant to the Company’s business and areas of research and development
and otherwise as either the Company or Board Member considers appropriate; (iv) develop, review and comment on the Company’s strategies for research and development, product definition, regulatory approvals, business development and
marketing, partnering, fund raising as well as its related presentations and materials; (v) provide consulting services to the Company at its request, including a reasonable amount of informal consultation in person, over the telephone, by
email, or otherwise as requested by the Company, at times reasonably convenient to Board Member; and (vi) with the Company’s approval in each instance, make introductions to individuals and corporations that might be of assistance to the
Company. 
 2.    TERM. The term of Board Member’s appointment and services under this Agreement will
commence as of the Effective Date and will continue through June 30, 2018 (the “Term”). Notwithstanding the foregoing, either Board Member or the Company may terminate this Agreement at any time by providing the other at least thirty
(30) days prior written notice, or as may be otherwise provided by Section 8 of this Agreement. Upon termination of this Agreement by either party for any reason, or upon expiration of the Term, Board Member will resign his position as a
director of the Company, as Chairman of the Board and as a member of any Board committees. 
 3.    COMPENSATION.

 (a)    STOCK OPTIONS. In consideration for service under this Agreement, Board Member has previously been
granted a non-statutory stock option to purchase 175,000 shares of common stock of the Company (the “Option Shares”) pursuant to and subject to the terms and conditions of the Company’s 2011
Equity Incentive Plan (the “Plan”), with an exercise price of $1.39 per Option Share, and with One-Twenty-Fourth (1/24th) of the Option Shares
vesting on July 31, 2016, and One-Twenty-Fourth (1/24th) of the Option Shares vesting on the last day of each month thereafter during the term of this
Agreement until fully vested, provided that Board Member continues to provide services to the Company under this Agreement as of any such vesting date. Notwithstanding anything to the contrary in the Plan or in the stock option agreement relating to
the Option Shares, in the event of Board Member’s continued service to the Company in another capacity following the termination of his directorship pursuant to this Agreement, the exercise period for all of Board Member’s vested Option
Shares as of the date of termination will be extended for the period of continued service by Board Member to the Company in another capacity. 

 (b)    EXPENSE REIMBURSEMENT. Board Member will be reimbursed for
reasonable travel and other out-of-pocket expenses incurred by Board Member in connection with the services provided by Board Member under this Agreement, provided that
(i) Board Member provides receipts and other reasonable documentation as requested by the Company and (ii) Board Member provides a written report of his expenses on a quarterly basis to the Chair of the Company’s Compensation
Committee for review. Board Member will also be expected to abide by any travel and/or out-of-pocket expense guidelines that are provided to him by the Company. Subject
to this Section 3(b), in the event Board Member’s air travel plans require Board Member to take a flight over three (3) hours in duration, the Company agrees to permit reimbursement for first-class air travel for that flight, to the extent
it is reasonably available. 
 4.    RETURN OF PROPERTY. Upon the termination of Board Member’s directorship
with the Company for any reason, Board Member will return to the Company all personal property belonging to the Company that is in Board Member’s possession or control as of the date of such termination, including, without limitation, all
Confidential Information (as defined below) and any documents related thereto; provided that, in the event of Board Member’s continued service to the Company in another capacity following the termination of his directorship pursuant to this
Agreement, Board Member shall be permitted to retain any such property to the extent it is necessary to fulfill Board Member’s obligations to the Company in such other capacity, subject to the terms and conditions governing such continued
service to the Company. Such Company property will be returned in the same condition as when provided to Board Member, reasonable wear and tear excepted. 

5.    CONFIDENTIALITY. Board Member shall keep in strict confidence and shall not disclose or make available to
third parties any information, technical data, know-how or documents relating to (i) Board Member’s services under this Agreement or (ii) the research, developments, inventions, processes, trade
secrets, data, techniques, designs, drawings, products, product plans, services, customers, marketing, software, finances, business methods, business or affairs or confidential or proprietary information of the Company (other than information in the
public domain through no fault of Board Member’s own) (collectively, “Confidential Information”), except with the prior written consent of the Company, and Board Member shall only use Confidential Information as necessary to perform
services on behalf of the Company under this Agreement or any other agreement pursuant to which Board Member is providing services on behalf of the Company. Board Member’s obligations under this Section 5 shall survive termination or
expiration of this Agreement for a period of three (3) years from the date of termination. Notwithstanding the foregoing, any trade secrets of the Company will be entitled to all of the protections and benefits under the North Carolina Trade
Secrets Protection Act and any other applicable law, and the protections provided for in this Section 5 will remain in effect indefinitely as to Confidential Information that is a trade secret (as defined by statute and common law). 

6.    INTELLECTUAL PROPERTY. Board Member shall promptly disclose and hereby transfers and assigns to the Company
all right, title and interest in and to all techniques, methods, processes, software, documents, formulae, improvements, inventions and discoveries 

  
 2 

 
(and any patents issuing thereon) made or conceived or reduced to practice by Board Member, solely or jointly with others, in the course of providing services hereunder or with the use of
materials or facilities of the Company, during the period of this Agreement, and all intellectual property rights related to any of the foregoing (collectively “Inventions”). Board Member shall not publish any such Invention without the
Company’s prior written consent. When requested by the Company, Board Member will make available to the Company all papers, notes, drawings, data and other information relating to any such Inventions. Board Member will promptly sign any
documents (including U.S. and foreign copyright, trademark and patent assignments) requested by the Company related to the above assignment of rights and such Inventions and will cooperate with the Company at the Company’s request and expense
in preparation and prosecution of any U.S. or foreign copyright, trademark or patent applications related to such rights and Inventions. Board Member’s obligations under this Section 6 shall survive termination or expiration of this
Agreement for the period of three (3) years from the date of termination. The obligations of Board Member under this Section 6 will not apply to a particular circumstance to the extent such obligations are unenforceable in such
circumstance pursuant to the provisions of North Carolina General Statute Section 66-57.1 et seq. (as amended from time to time), provided that the obligations of Board Member under Section 6 will
continue to be binding upon Board Member in all other circumstances. Board Member will bear the burden of proof in establishing the applicability of such statute to a particular circumstance. 

7.    ENFORCEMENT. Board Member acknowledges and agrees that the Company will suffer irreparable harm in the event
that Board Member breaches any of Board Member’s obligations under Sections 4, 5 or 6 of this Agreement and that monetary damages would be inadequate to compensate the Company for such breach. Accordingly, Board Member agrees that, in the event
of a breach by Board Member of any of Board Member’s obligations under Sections 4, 5 or 6 of this Agreement, the Company will be entitled to obtain from any court of competent jurisdiction preliminary and permanent injunctive relief, and
expedited discovery for the purpose of seeking relief, in order to prevent or to restrain any such breach. The Company will be entitled to recover its costs incurred in connection with any action to enforce Sections 4, 5 or 6 of this Agreement,
including reasonable attorneys’ fees and expenses, to the maximum extent permitted by law. 
 8.    NOTICE OF
OUTSIDE ACTIVITIES. Board Member acknowledges that the services to be performed for the Company hereunder are essential to the Company and, therefore, during the Term hereof, Board Member will provide prior written notice to the Company of any
consulting projects for or outside employment with companies whose business would be, “Directly Competitive” with the business of the Company. Following its receipt of such notification, the Company may terminate this Agreement at any time
effective immediately. “Directly Competitive” shall mean companies that engage in the research and development and/or sale of selective CDK4/6 inhibitors. The Company acknowledges Board Member’s commitments to Liquidia (and any of its
derivative companies), Aralez Pharmaceuticals, Square l Bank, Emory’s DRIVE Enterprise, Meryx and Abyrx are not directly competitive to this Company. 

9.    INDEPENDENT CONTRACTOR. Board Member’s relationship with the Company shall be that of an independent
contractor and Board Member will not be considered an employee of the Company. Board Member will not be eligible for any employee benefits, nor will 

  
 3 

 
the Company make deductions from payments made to Board Member for any taxes or other withholding obligations, which shall be Board Member’s responsibility. Board Member shall not have
authority to enter into contracts that bind the Company or create obligations on the part of the Company without the express, prior authorization of the Company. 

10.    NOTICES. Any notice required to be given hereunder will be sufficient if in writing and hand delivered or
sent by mail, return receipt requested, postage prepaid, in the case of Board Member, to his address shown on the Company’s records, and in the case of the Company, to 79 TW Alexander Drive, 4401 Research Commons, Suite 105, Research Triangle
Park, North Carolina 27709, or to such other addresses as either party shall specify to the other. 

11.    WAIVER. No waiver of any provision of this Agreement will be valid unless the same is in writing and signed
by the party against whom such waiver is sought to be enforced. Failure to insist upon strict compliance with any of the terms, covenants or conditions hereof will not be deemed a waiver of such terms, covenants or conditions, nor will any waiver or
relinquishment of any right or power granted hereunder at any particular time be deemed a waiver or relinquishment of such rights or power at any other time or times. 

12.    GOVERNING LAW; VENUE. This Agreement will be governed by and construed in accordance with the laws of the
State of North Carolina, without regard to that body of law known as choice of law. The parties agree that any litigation arising out of or related to this Agreement or Board Member’s directorship with the Company will be brought exclusively in
any state or federal court in Orange County, North Carolina. Each party (i) consents to the personal jurisdiction of said courts, (ii) waives any venue or inconvenient forum defense to any proceeding maintained in such courts, and
(iii) agrees not to bring any proceeding arising out of or relating to this Agreement or Board Member’s directorship with the Company in any other court. 

13    BENEFIT. This Agreement will be binding upon and will inure to the benefit of each of the parties hereto, and
to their respective heirs, representatives, successors and permitted assigns. Board Member may not assign any of his rights or delegate any of his duties under this Agreement. 

14.    ENTIRE AGREEMENT. This Agreement contains the entire agreement and understanding by and between the Company
and Board Member with respect to the terms described herein, and any representations, promises, agreements or understandings, written or oral, not herein contained will be of no force or effect. No change or modification hereof will be valid or
binding unless the same is in writing and signed by the parties hereto. 
 15.    CAPTIONS; RULE OF CONSTRUCTION.
The captions in this Agreement are for convenience only and in no way define, bind or describe the scope or intent of this Agreement. The terms and provisions of this Agreement will not be construed against the drafter or drafters hereof. All
parties hereto agree that the language of this Agreement will be construed as a whole according to its fair meaning and not strictly for or against any of the parties hereto. 

16.    COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which will be
deemed an original but all of which together will constitute one and the same agreement. Facsimile or PDF reproductions of original signatures will be deemed binding for the purpose of the execution of this Agreement. 

  
 4 

 17.    SEVERABILITY. Each provision of this Agreement is severable
from every other provision of this Agreement. Any provision of this Agreement that is determined by any court of competent jurisdiction to be invalid or unenforceable will not affect the validity or enforceability of any other provision. Any
provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. 

18.    SURVIVAL. The terms of Sections 4 through 7 and 9 through 18 will survive the termination or expiration of
this Agreement for any reason. 
 IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date. 

 

			
	G1 THERAPEUTICS, INC:
		
	By:	 	 /s/ Mark Velleca

	Name:	 	Mark Velleca, MD, PhD
	Title:	 	Chief Executive Officer
	
	BOARD MEMBER:
	
	 /s/ Seth Rudnick

	Seth Rudnick, MD

  
 5EX-10.9

 Exhibit 10.9 

ADVISORY BOARD MEMBER AGREEMENT 

Seth Rudnick, M.D. 
 Dear Dr. Rudnick: 

This ADVISORY BOARD MEMBER AGREEMENT (the “Agreement”), is made and entered into as of this 15th day of July 2016 and effective as of July 1, 2016 (the “Effective Date”), by and between G1 Therapeutics, Inc., a Delaware corporation (the
“Company”), and you. This Agreement replaces that certain Advisory Board Member Agreement, effective July 1, 2014, by and between the Company and you, which expired by its terms on June 30, 2016. 

1.    Services. The Company wishes to retain your services as a member of the Company’s Scientific Advisory
Board (“SAB”) and Clinical Advisory Board (“CAB”), pursuant to which you will be expected to attend any meetings of the SAB and CAB, and fulfill the additional responsibilities of an SAB and CAB member as described on Exhibit
A and Exhibit A-1, respectively attached hereto. This Agreement (including the exhibits hereto) shall constitute an agreement between you and the Company and contain all the terms and conditions
relating to the services you are to provide. 
 2.    Term. The Company expects that the term of this Agreement
shall be for two years starting on the Effective Date and ending on June 30, 2018 (the “Term”). Notwithstanding the foregoing, either you or the Company may terminate this Agreement at any time by providing
the other at least thirty (30) days prior written notice, or as may be otherwise provided in this Agreement. 

3.    Consideration. As consideration for your services and other obligations during the Term, the Company will pay
you cash compensation in the amount of Six Thousand Dollars ($6,000) annually, payable in two equal semi-annual installments (the “Annual Fee”). The Annual Fee installments shall be paid within thirty (30) days of
receipt of an invoice from you.    In addition, the Company shall pay you cash compensation for each SAB or CAB meeting attended, or any other advisory meeting requested by the Company, (the “Meeting
Fee”). The Meeting Fee will be equal to Three Thousand Dollars ($3,000) for each SAB or CAB meeting attended in person and One Thousand Five Hundred Dollars ($1,500) for each SAB or CAB meeting attended by phone or conference call. The
Meeting Fee for any meetings that take place shall be paid within thirty (30) days of receipt of an invoice from you 

4.    Expenses. You shall be reimbursed for reasonable travel and other out-of-pocket expenses incurred by you in connection with your services under this Agreement, provided that (i) you provide receipts and other reasonable documentation as requested by the Company and
(ii) any such expenses in excess of $500.00 must be approved in advance, either verbally or in writing by the Company. You will also be expected to abide by any travel and/or
out-of-pocket expense guidelines that are provided to you by the Company. You are permitted to use your private aircraft at the IRS reimbursement rate with prior Company
authorization, either verbally or in writing. 

 5.    Independent Contractor. Your relationship with the Company shall
be that of an independent contractor and you will not be considered an employee of the Company. You will not be eligible for any employee benefits, nor will the Company make deductions from payments made to you for any taxes or other withholding
obligations, which shall be your responsibility. You shall not have authority to enter into contracts that bind the Company or create obligations on the part of the Company without the express, prior authorization of the Company. 

6.    Performance. All services to be performed by you will be as agreed between you and the Chief Executive
Officer of the Company. Except as required for attendance at SAB and CAB meetings or specifically requested by the Company, the manner in which the services are to be performed and the specific hours to be worked shall be determined by you. You
shall report to the Chief Executive Officer, or other Company officer designated by the Company, concerning your services performed under this Agreement. 

7.    Confidentiality. You shall keep in strict confidence and shall not disclose or make available to third
parties any information, technical data, know-how or documents relating to (i) your services under this Agreement or (ii) the research, developments, inventions, processes, trade secrets, data,
techniques, designs, drawings, products, product plans, services, customers, marketing, software, finances, business methods, business or affairs or confidential or proprietary information of the Company (other than information in the public domain
through no fault of your own) (collectively, “Confidential Information”), except with the prior written consent of the Company, and you shall only use Confidential Information as necessary to perform services on behalf of the
Company under this Agreement or any other agreement pursuant to which you are providing services on behalf of the Company. Upon termination of this Agreement, you will destroy or return to the Company all documents and other materials related to the
services provided hereunder or furnished to you by the Company provided that, in the event of your continued service to the Company in another capacity following the termination of this Agreement, you shall be permitted to retain any such property
to the extent it is necessary to fulfill your obligations to the Company in such other capacity, subject to the terms and conditions governing such continued service to the Company. Your obligations under this Paragraph 7 shall survive termination
of this Agreement for a period of three (3) years from the date of termination. 
 8.    Intellectual
Property. You shall promptly disclose and hereby transfer and assign to the Company all right, title and interest to all techniques, methods, processes, software, documents, formulae, improvements, inventions and discoveries (and any patents
issuing thereon) made or conceived or reduced to practice by you, solely or jointly with others, in the course of providing services hereunder or with the use of materials or facilities of the Company, during the period of this Agreement, and all
intellectual property rights related to any of the foregoing (collectively “Inventions”). You shall not publish any such Invention without the Company’s prior written consent. When requested by the Company, you will make
available to the Company all papers, notes, drawings, data and other information relating to any such Inventions. You will promptly sign any documents (including U.S. and foreign copyright, trademark and patent assignments) requested by the Company
related to the above assignment of rights and such Inventions and will cooperate with the Company at the Company’s request and expense in preparation and prosecution of any U.S. or foreign copyright, trademark or patent applications related to
such rights and Inventions. Your obligations under this Paragraph 8 shall survive termination of this Agreement for the period of three (3) years from the date of termination. 

  
 2 

 9.    Notice of Consulting Activities. You acknowledge that the
services to be performed for the Company hereunder are essential to the Company and, therefore, during the term hereof, you will provide prior written notice to the Company of any consulting projects for companies whose business would be,
“Directly Competitive” with the business of the Company. Following its receipt of such notification, the Company may terminate this Agreement at any time effective immediately. “Directly Competitive” shall mean companies that
engage in the research and development and/or sale of selective CDK4/6 inhibitors. The Company acknowledges your commitments to Liquidia (and any of its derivative companies), Aralez Pharmaceuticals, Square l Bank, Emory’s DRIVE Enterprise,
Meryx and Abyrx are not being directly competitive to this Company. 
 10.    Amendment. Any amendment to this
Agreement must be in a writing signed by you and the Company. 
 11.    Notice. All notices, requests and other
communications called for by this Agreement shall be deemed to have been given when received if made in writing and mailed, return receipt requested, postage prepaid, if to you at the address set forth above and if to the Company to 79 TW Alexander
Drive, 4401 Research Commons, Suite 105, Research Triangle Park, North Carolina 27709, or to such other addresses as either party shall specify to the other. 

12.    Indemnification. You agree to indemnify and hold the Company harmless from all claims, losses, expenses,
fees including reasonable attorneys’ fees, costs and judgments that may be asserted against the Company that result from the acts or omissions of you under this Agreement. The Company agrees to indemnify and hold you harmless from all claims,
losses, expenses, fees, including reasonable attorneys’ fees, costs and judgments, that may be asserted against you that relate to the Company except such claims, losses, expenses and fees that result from your acts or omissions under this
Agreement. 
 13.    Governing Law; Jurisdiction. This Agreement shall be interpreted and construed in accordance
with the laws of the State of North Carolina, excluding that body of law known as choice of law. All disputes with respect to this Agreement shall be brought and heard either in the North Carolina state courts located in Orange County, North
Carolina, or the federal district court for the Eastern District of North Carolina located in Raleigh, North Carolina. The parties to this Agreement each consent to the in personam jurisdiction and venue of such courts. The parties agree that
service of process upon them in any such action may be made if delivered in person, by courier service, by telegram, by telefacsimile or by first class mail, and shall be deemed effectively given upon receipt. 

14.    Entire Agreement. This Agreement is the entire agreement between the parties regarding the subject matter
hereof and there are no other promises or conditions in any other agreement whether oral or written. This Agreement supersedes any prior consulting or other agreements with respect to the subject matter hereof between you and the Company. 

  
 3 

 15.    Assignment. This Agreement shall be for the benefit of, and
shall be binding upon, the successors and assigns of the parties hereto. You agree not to assign this Agreement without the prior written consent of the Company. 

(NEXT PAGE IS SIGNATURE PAGE) 

  
 4 

 If this Agreement is satisfactory, please indicate your acceptance of these terms by your
signature below. 
  

			
	Very truly yours,
	
	G1 THERAPEUTICS, INC.
		
	By:	 	 /s/ Mark Velleca

	Name:	 	Mark Velleca, MD, PhD
	Title:	 	Chief Executive Officer

  

	
	AGREED AND ACCEPTED:
	
	 Seth Rudnick, M.D.

	(Typed or printed name)
	
	 /s/ Seth Rudnick

	(Signature)

 EXHIBIT A 

Advisor’s Responsibilities – SAB 

As a member of the Company’s Scientific Advisory Board, Seth Rudnick (the “Advisor”) will make best efforts to: 

1.     Attend meetings of the Scientific Advisory Board expected to take place approximately twice per year. 

2.     Provide guidance and advice to the Company on scientific and technological matters and developments potentially relevant to the
Company’s business and areas of research and development and otherwise as either the Company or Advisor considers appropriate. 

3.    Develop, review and comment on the Company’s strategies for research and development, product definition, regulatory approvals,
business development and marketing, as well as its related presentations and materials. 
 4.    Provide consulting services to the
Company at its request, including a reasonable amount of informal consultation in person, over the telephone, by email, or otherwise as requested by the Company at times reasonably convenient to Advisor. 

5.    With the Company’s approval in each instance, make introductions to individuals and corporations that might be of assistance to
the Company. 

 EXHIBIT A-1 

ADVISOR’S RESPONSIBILITIES - CAB 
 As
a member of the Company’s Clinical Advisory Board, Seth Rudnick (the “Advisor”) will make best efforts to: 
  

	1.	Attend all Clinical Advisory Board meetings. 

  

	2.	Provide any material reasonably requested by the Company that is relevant to the Company’s clinical development/testing plans and to which Advisor has reasonable access. 

 

	3.	Review and comment on the Company’s clinical development/testing plans. 

  

	4.	Other services related to the Company’s clinical development programs to be provided as appropriate and/or requested by the Company, in each case subject to a written addendum to this agreement setting forth the
particular services and the compensation to be paid for such services.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]